Key Highlights
- BD's $1.05 quarterly Dividend trades ex-date September 9, 2026, payable September 30, implying an annualized rate of $4.20 per share.
- Third-quarter Revenue reached $5.0 billion, up 4.4% on an FX-neutral basis, with adjusted EPS of $3.23, both ahead of expectations.
- Year-to-date free Cash Flow rose 44.6% to $1.7 billion, supporting $3.1 billion in year-to-date Shareholder returns.
- Results reflect BD's first full quarter as a standalone MedTech company following the February 2026 Biosciences and Diagnostic Solutions spin-off.
Becton, Dickinson's (NYSE:BDX) $1.05 quarterly dividend yields approximately 2.27%, a payout now measured against a meaningfully different company than a year ago. The more consequential story this quarter is the completed February 2026 spin-off of BD's Biosciences and Diagnostic Solutions business, which means every growth comparison investors see is now against a leaner, more focused medtech portfolio, one management says is already showing broad-based strength across its remaining platforms.
Dividend Program and Shareholder Returns
BD declared a quarterly dividend of $1.05 per common share, approved July 28, 2026, payable September 30 to holders of record September 9, implying an indicated annual rate of $4.20 per share. The dividend is well supported by growing cash generation: year-to-date free cash flow rose 44.6% to $1.7 billion, and the company returned $3.1 billion to shareholders through the first nine months of fiscal 2026, including approximately $2.3 billion in share repurchases and $0.9 billion in dividends.
About the Company
Becton, Dickinson is one of the world's largest pure-play medical technology companies, headquartered in Franklin Lakes, New Jersey. Following the February 9, 2026 spin-off of its Biosciences and Diagnostic Solutions segment, BD now operates as a more focused company across Medical Essentials, Connected Care, BioPharma Systems and Interventional platforms, serving hospitals, laboratories and healthcare providers globally with medication delivery, vascular and interventional technologies.
Financial Performance Behind the Payout
BD reported third-quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on an FX-neutral basis. GAAP diluted EPS from continuing operations was $1.64, while adjusted diluted EPS was $3.23, up 4.9% year over year and ahead of the company's own expectations. More than 90% of the portfolio grew at high-single-digit rates or better, led by double-digit gains in biologic drug delivery, advanced patient monitoring, PureWick and tissue regeneration. Adjusted Operating Margin was 24.9%, down 130 basis points on Tariff impact, while net Leverage stood at approximately 2.9 times, above the company's long-term 2.5 times target.
A Cleaner Portfolio Is Driving the Growth Story
BD's post-spin-off portfolio is proving more focused and, so far, faster-growing than the combined entity was: management highlighted that this was the first full quarter as a standalone medtech company, and more than 90% of remaining businesses are growing at high-single-digit rates. The offsetting Factor is elevated net leverage, still above BD's own long-term target, meaning continued deleveraging will compete with dividend growth and reinvestment for available cash. Tariffs added roughly 110 basis points of margin pressure this quarter, a headwind productivity gains only partially offset.
Outlook
BD's dividend is supported by strong and growing free cash flow, though sustained increases will depend on continued deleveraging toward the 2.5 times net-leverage target and on tariff-related cost pressure easing as previously guided. Investors should watch organic revenue growth across the four core platforms, adjusted operating margin trends, net leverage progress and free cash flow conversion.
Yes, materially. February 2026's spin-off means all current results reflect continuing operations only, a leaner portfolio now posting stronger growth than the prior combined company.
Not immediately. At about 2.9 times, leverage remains manageable and free cash flow is growing sharply, though it does mean deleveraging will compete with other Capital priorities near term.
Broad-based platform strength. Over 90% of the post-spin-off portfolio is growing at high-single-digit rates, led by biologic drug delivery, patient monitoring and tissue regeneration.

_09_30_2026_02_08_20_566201.jpg)




Please wait processing your request...